延安必康:擬投資500萬元於利巴韋林注射液等藥品生產
格隆匯2月11日丨延安必康(002411.SZ)公佈,公司於近日向延安市人民政府提交了《關於協調新型冠狀病毒疫情防疫重要藥品利巴韋林小容量注射劑委託生產手續緊急請示》,並於2020年2月10日收到延安市人民政府下發的《關於延安必康辦理利巴韋林注射液等藥品委託生產手續的覆函》,延安市政府將按照特事特辦、急事急辦的原則,開闢應急綠色通道,全力支持公司整合內部資源,加快利巴韋林注射液等重要藥品落地投產投放,力爭利巴韋林注射液達到年產6000萬支產能,利巴韋林片年產10億片產能。
公司為響應國家和地方政府的號召,以實際行動支持新型冠狀病毒的防疫工作,踐行上市公司社會責任,擬投資人民幣500.00萬元支持公司下屬子公司利巴韋林注射液等藥品的生產,資金來源為公司自有資金。主要用於原輔包的採購,生產設備所需購買相應規格的模具等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.